Status of the inner retinal layers in patients with multiple sclerosis
Part 4: What if? Curing any eye disease with the snap of your finger
We ask leading experts in the field what eye disease they would cure and why.
Viridian Therapeutics completes enrollment in REVEAL-1 and REVEAL-2 clinical trials for VRDN-003
Viridian plans to submit a Biologics License Application (BLA) for VRDN-003 by year-end of 2026.
Ocugen and Kwangdong complete licensing agreement for OCU400 gene therapy in Korea
Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”
Long-term atropine use linked to higher risk of ocular complications in children
Q&A: Elon van Dijk on central serous chorioretinopathy.
Q&A: María Berrocal's Ingrid Kreissig Award Lecture at EURETINA 2025
Optain Health secures $26 million Series A funding
Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.
Q&A: Marion Munk on IntRIS symposium at EURETINA 2025
Researchers propose new explanation for drusen regression without atrophy
A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.
Part 3: What if? Curing any eye disease with the snap of your finger
Q&A: Giuseppe Querques on PVAC and TelCaps
Bausch + Lomb announce publication, positive topline results of enVista Envy trial data
Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.
New company OpZira formed following Alcon’s acquisition of LumiThera
OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.
SAR402663 earns fast track designation for treatment of nAMD
Alcon announces launch of wavelight plus, fully personalized LASIK treatment, in US and Canada
Wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit
Q&A: Timothy Lai on the SALWEEN trial
Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.
EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye
From lids to retina, the 2-day event on September 26 and 27, 2025, at the Margaritaville Hollywood Beach Resort, Florida, offers a collaborative and comprehensive experience with actionable takeaways.
Part 2: What if? Curing any eye disease with the snap of your finger
Effects of calcium channel blockers on visual field progression in glaucoma patients
Study links AMD to higher cardiovascular disease mortality in high-risk patients
The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.
Sandoz and Regeneron reach agreement over biosimilar dispute
Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.
Using OCT-A to explore biomarkers for neurodegenerative diseases
UnitedHealthcare updates Glaucoma Surgical Treatments policy
This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.
Positive topline data announced from AVONELLE-X and SALWEEN trials
Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.
Q&A: Amir Kashani on biomarkers for Alzheimer disease
OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
Part 1: What if? Curing any eye disease with the snap of your finger
The start of the series that asks leading experts in the field what eye disease they would cure and why.
Celltrion announces phase 3 trial data for EYDENZELT
